Rein Therapeutics Inc (RNTX)

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)First patient randomized...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Total gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:...

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8...